Ellex Shareholders to vote on Lumibird transaction
24 March, 2020
Whether they are suffering from glaucoma, retinal disease, age-related macular degeneration or cataracts, it's a significant number of people, and, with the population within many countries aging, it's likely that this figure will continue to rise.
It's within this context that the market opportunity for investors in a business like Ellex becomes more significant. With over 35,000 Ellex ophthalmic laser and diagnostic ultrasound systems in use in over 100 countries around the world, we have established a strong reputation for excellence in clinical performance.
We have built on this foundation with the integration of iTrack™ for minimally invasive glaucoma surgery (MIGS), and through our 2RT™ Retinal Rejuvenation Therapy, we're now able to equip physicians with the technology to proactively stimulate the eye's natural healing response in the intervention of early AMD, the world’s leading cause of blindness.
Ellex is a business that is investing for the future: a future where we can help address the treatment needs and transform the sight of people across the globe. Our purpose-built laser and ultrasound production facility in Adelaide, Australia, teamed with our state-of-the-art iTrack production facility in California, USA, enables us to manufacture our ophthalmic technology to the highest level of precision and quality.
With sales and service subsidiaries in California and Minnesota, Japan, France, Germany and Australia, Ellex is a truly global enterprise. Our network of more than 50 distributors in over 100 countries means that we possess a robust route to market. It’s a strength that enables us to equip ophthalmologists with our proprietary technologies around the world — and it’s a business with the commercial potential to continue to grow significantly in the years ahead.